Cocrystal Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2834 www.cocrystalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma, Inc.

COCP: CDI-988 Data to be Presented at ICAR 2026 - Feb 23rd, 2026 5:31 am
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 - Feb 19th, 2026 6:00 am
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - Dec 18th, 2025 6:00 am
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference - Dec 1st, 2025 6:00 am
COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26… - Nov 18th, 2025 4:21 am
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Nov 14th, 2025 6:00 am
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules - Oct 30th, 2025 6:00 am
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program - Oct 27th, 2025 6:00 am
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference - Oct 2nd, 2025 6:00 am
COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million… - Sep 17th, 2025 7:44 am
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Sep 15th, 2025 2:30 pm
BC-Most Active Stocks - Sep 12th, 2025 8:30 am
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Sep 12th, 2025 7:43 am
Wall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report - Sep 12th, 2025 7:21 am
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference - Sep 12th, 2025 6:00 am
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment - Sep 8th, 2025 6:00 am
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference - Sep 3rd, 2025 6:00 am
COCP: Norovirus Challenge Study to Initiate in 4Q25… - Aug 19th, 2025 8:12 am
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Aug 14th, 2025 6:00 am
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference - Aug 5th, 2025 6:00 am